Hidayat Yudi Mulyana, Harsono Ali Budi, Winarno Gatot Nyarumenteng Adhipurnawan, Salima Siti
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Syiah Kuala, Aceh, Indonesia.
Int J Gen Med. 2020 Nov 20;13:1201-1206. doi: 10.2147/IJGM.S280858. eCollection 2020.
The ultimate goal of cytoreduction surgery is the complete removal of all visible tumors (complete cytoreductive surgery) or tumor residues <1 cm (optimal cytoreduction surgery). Following cytoreduction surgery in ovarian cancer, tumor residue is one of the most important prognostic factors. Oncologists strive to be able to predict the outcome of cytoreduction surgery during the presurgical period. The purpose of this study was to assess CCL5 as a modality for determining whether a patient could perform optimal cytoreduction surgery or not.
This was an observational, analytic, and cross-sectional study of patients with ovarian cancer who underwent surgery at the Dr. Hasan Sadikin Bandung from 2019 to 2020. All of the patients had stage I-IV disease based on the International Federation of Gynecology and Obstetrics (FIGO) score.
In total, 72 patients were enrolled in this study, 31 of whom underwent suboptimal cytoreduction surgery and 41 underwent optimal cytoreduction surgery. The mean serum CCL5 level at suboptimal cytoreduction was 70,920.87 ± 36,362.966, while that at optimal cytoreduction was 43,244.95 ± 21,983.887. CCL5, as a predictor of suboptimal cytoreduction surgery, had a sensitivity of 61.3%, a specificity of 68.3%, and an accuracy of 65.7% (p = 0.012).
Preoperative CCL5 serum levels can predict suboptimal cytoreduction surgery outcomes in patients with ovarian cancer.
肿瘤细胞减灭术的最终目标是完全切除所有可见肿瘤（完全细胞减灭术）或肿瘤残留<1 cm（最佳细胞减灭术）。在卵巢癌患者接受细胞减灭术后，肿瘤残留是最重要的预后因素之一。肿瘤学家致力于在术前阶段就能预测细胞减灭术的结果。本研究的目的是评估CCL5作为一种确定患者是否能够进行最佳细胞减灭术的方法。
这是一项对2019年至2020年在万隆哈桑·萨迪金博士医院接受手术的卵巢癌患者进行的观察性、分析性和横断面研究。所有患者根据国际妇产科联盟（FIGO）评分处于I-IV期疾病。
本研究共纳入72例患者，其中31例行次优细胞减灭术，41例行最佳细胞减灭术。次优细胞减灭术时血清CCL5平均水平为70,920.87±36,362.966，而最佳细胞减灭术时为43,244.95±21,983.887。CCL5作为次优细胞减灭术的预测指标，敏感性为61.3%，特异性为68.3%，准确性为65.7%（p = 0.012）。
术前血清CCL5水平可预测卵巢癌患者次优细胞减灭术的结果。
